TCF3 and colorectal carcinoma: In view of the comprehensive data presented in this study, we propose that over-expression of TCF3 in stage II and III CRC patients was significantly associated with poor prognosis and low disease-free survival rate (Figure 3), which contributes to identify those high- risk CRC patients.